These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20946973)

  • 21. Comment on "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status".
    Pappagallo M; Inturrisi CE; Manfredi PL
    CNS Drugs; 2022 Feb; 36(2):203-204. PubMed ID: 35015265
    [No Abstract]   [Full Text] [Related]  

  • 22. Is there a personalized medicine for mood disorders?
    Bartova L; Berger A; Pezawas L
    Eur Arch Psychiatry Clin Neurosci; 2010 Nov; 260 Suppl 2():S121-6. PubMed ID: 20957381
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Magnetic resonance spectroscopic studies of pediatric mood disorders: a selective review.
    Unal SS; Port JD; Mrazek DA
    Curr Opin Pediatr; 2005 Oct; 17(5):619-25. PubMed ID: 16160537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1H-magnetic resonance spectroscopy study of glutamate-related abnormality in bipolar disorder.
    Kubo H; Nakataki M; Sumitani S; Iga JI; Numata S; Kameoka N; Watanabe SY; Umehara H; Kinoshita M; Inoshita M; Tamaru M; Ohta M; Nakayama-Yamauchi C; Funakoshi Y; Harada M; Ohmori T
    J Affect Disord; 2017 Jan; 208():139-144. PubMed ID: 27770643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rapid phenotyping towards personalized malaria medicine.
    Veiga MI; Peng WK
    Malar J; 2020 Feb; 19(1):68. PubMed ID: 32046739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unmet needs in developing nanoparticles for precision medicine.
    Schwartz S
    Nanomedicine (Lond); 2017 Feb; 12(4):271-274. PubMed ID: 28093937
    [No Abstract]   [Full Text] [Related]  

  • 27. Cluster analysis reveals abnormal hippocampal neurometabolic profiles in young people with mood disorders.
    Hermens DF; Naismith SL; Chitty KM; Lee RS; Tickell A; Duffy SL; Paquola C; White D; Hickie IB; Lagopoulos J
    Eur Neuropsychopharmacol; 2015 Jun; 25(6):836-45. PubMed ID: 25795519
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brainstem metabolites in multiple system atrophy of cerebellar type: 3.0-T magnetic resonance spectroscopy study.
    Takado Y; Igarashi H; Terajima K; Shimohata T; Ozawa T; Okamoto K; Nishizawa M; Nakada T
    Mov Disord; 2011 Jun; 26(7):1297-302. PubMed ID: 21370263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An Overview of Drug Delivery Systems.
    Jain KK
    Methods Mol Biol; 2020; 2059():1-54. PubMed ID: 31435914
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics.
    Ortiz R; Ulrich H; Zarate CA; Machado-Vieira R
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Mar; 57():117-31. PubMed ID: 25445063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glutamatergic function in a genetic high-risk group for psychosis: A proton magnetic resonance spectroscopy study in individuals with 22q11.2 deletion.
    Rogdaki M; Hathway P; Gudbrandsen M; McCutcheon RA; Jauhar S; Daly E; Howes O
    Eur Neuropsychopharmacol; 2019 Dec; 29(12):1333-1342. PubMed ID: 31648854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Radiolabeled imaging probes targeting angiogenesis for personalized medicine.
    Terry SY; Rijpkema M; Abiraj K; van der Graaf WT; Oyen WJ; Boerman OC
    Curr Pharm Des; 2014; 20(14):2293-307. PubMed ID: 24025101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The problem of spurious correlations between pairs of brain metabolite values measured in the same voxel with magnetic resonance spectroscopy.
    Maddock R
    JAMA Psychiatry; 2014 Mar; 71(3):338-9. PubMed ID: 24599243
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical studies implementing glutamate neurotransmission in mood disorders.
    Sanacora G; Rothman DL; Mason G; Krystal JH
    Ann N Y Acad Sci; 2003 Nov; 1003():292-308. PubMed ID: 14684453
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An Exploratory Study of Spectroscopic Glutamatergic Correlates of Cortical Excitability in Depressed Adolescents.
    Lewis CP; Port JD; Frye MA; Vande Voort JL; Ameis SH; Husain MM; Daskalakis ZJ; Croarkin PE
    Front Neural Circuits; 2016; 10():98. PubMed ID: 27965544
    [No Abstract]   [Full Text] [Related]  

  • 36. (13)C magnetic resonance spectroscopy and glutamate metabolism in mood disorders: current challenges, potential opportunities.
    Bond DJ; Lim KO
    Am J Psychiatry; 2014 Dec; 171(12):1240-2. PubMed ID: 25756763
    [No Abstract]   [Full Text] [Related]  

  • 37. Materializing Personalized Medicine.
    Artzi N
    Adv Mater; 2020 Apr; 32(13):e1908065. PubMed ID: 32237118
    [No Abstract]   [Full Text] [Related]  

  • 38. Medicine's secret ingredient - it's in the timing.
    Peeples L
    Nature; 2018 Apr; 556(7701):290-292. PubMed ID: 29666501
    [No Abstract]   [Full Text] [Related]  

  • 39. What have we learned from proton magnetic resonance spectroscopy about schizophrenia? A critical update.
    Abbott C; Bustillo J
    Curr Opin Psychiatry; 2006 Mar; 19(2):135-9. PubMed ID: 16612192
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmaceutical Additive Manufacturing: a Novel Tool for Complex and Personalized Drug Delivery Systems.
    Zhang J; Vo AQ; Feng X; Bandari S; Repka MA
    AAPS PharmSciTech; 2018 Nov; 19(8):3388-3402. PubMed ID: 29943281
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.